Want to join the conversation?
Drug giant $LLY reported a 12% rise in 4Q15 earnings on lower asset impairment, restructuring charges, and higher margin. Net income rose to $478.4MM or $0.45 per share from $428.5MM or $0.40 per share last year. Revenue rose 5% to $5.38Bil. But, non-GAAP EPS slid 5% to $0.78, due to termination costs for evacetrapib and basal insulin peglispro.
Late realization to $T that it cannot compete in the unlimited data market with its existing plans! Its newly launched plans seem more reasonable.
Wow, the new $HPE Pro x2 612 G2. Finally, a Surface Tab you can use for business!